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Several plants from South America show strong antitumoral properties based on anti-
proliferative and/or pro-apoptotic activities. In this work we aimed to identify selective
cytotoxic compounds that target BRCA1-deficient cancer cells by Synthetic Lethality (SL)
induction. Using a high-throughput screening technology developed in our laboratory, we
analyzed a collection of extracts from 46 native plant species from Argentina using a wide
dose-response scheme. A highly selective SL-induction capacity was found in an alkaloidal
extract from Zanthoxylum coco (Fam. Rutaceae). Bio-guided fractionation coupled to
HPLC led to the identification of active benzophenanthridine alkaloids. The most potent SL
activity was found with the compound oxynitidine, which showed a remarkably low relative
abundance in the active fractions. Further validation experiments were performed using the
commercially available and closely related analog nitidine, which showed SL-induction
activity against various BRCA1-deficient cell lines with different genetic backgrounds, even
in the nanomolar range. Exploration of the underlying mechanism of action using BRCA1-
KO cells revealed AKT and topoisomerases as the potential targets responsible of nitidine-
triggered SL-induction. Taken together, our findings expose an unforeseen therapeutic
activity of alkaloids from Zanthoxylum-spp. that position them as novel lead molecules for
drug discovery.
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INTRODUCTION
BRCA1 is highly characterized as a tumor suppressor gene that was originally identified in
hereditary breast and ovarian cancers (King et al., 2012; Takaoka and Miki, 2018). Nevertheless,
there is increasing evidence indicating that alterations in BRCA1, such as mutations or
epigenetic downregulation, are also recurrently found in sporadic cancers, being the
genome instability triggered by BRCA1 deficiency the driving force of tumorigenesis
(Fackenthal and Olopade, 2007; Venkitaraman, 2014). Moreover, several recent clinical
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studies have shown that BRCA1-deficient phenotypes are
found with high prevalence not only in breast and ovarian
cancers, but also in pancreatic, prostatic, and other types of
cancers (Lord and Ashworth, 2016).
A strategy that takes advantage of the genetic differences of
cancer cells to achieve their selective death is known as synthetic
lethality (SL), which consists in the simultaneous inactivation of
compensatory or redundant molecular pathways (Canaani,
2013; Nijman and Friend, 2013; Ryan et al., 2018). In this
sense, in a BRCA1-deficient context, the inhibition of specific
molecular targets that compensate BRCA1 functions could
trigger SL. A successful example of SL-induction to target
BRCA-deficient cancers is the development and approval of
PARP inhibitors (PARPi) (Kohn et al., 2017; Lord and
Ashworth, 2017), which have recently reached different types
of clinical settings (Golan et al., 2019; González-Martín et al.,
2019; Saleh and Copur, 2019) (https://www.fda.gov/drugs/drug-
approvals-and-databases/fda-approves-niraparib-first-line-
maintenance-advanced-ovarian-cancer). While PARPi exploit
the convergent roles of BRCA1, BRCA2 and other genes
involved in Homologous Recombination (HR) DNA repair,
BRCA1 also functions in many other cellular processes that
set the ground for novel SL-induction scenarios (Venkitaraman,
2014; Sharma et al., 2018; Simhadri et al., 2019). Moreover,
given that many types of resistance mechanisms to PARPi are
already being described (D’Andrea, 2018; Noordermeer and van
Attikum, 2019), there is a major interest in developing
alternative SL strategies to target BRCA1 deficiency from
different angles.
From an historical perspective, natural products
contributed to the origin of medicine. They provide a
great diversity of metabolites and present structural
features that synthetic compounds do not have (Henkel
et al., 1999; Rodrigues et al., 2016; Newman and Cragg,
2020), so it is not surprising that many of the available
drugs derive from plants and microorganisms (Harvey,
2008; Thomford et al., 2018). The enormous impact of
natural products in oncology drug discovery cannot be
overestimated. Nearly 50% of antineoplastic agents or
drugs in clinical trials are either natural products or
derived compounds (Bindseil et al., 2001; Schmidt et al.,
2007; Trendowski, 2015; Dutta et al., 2019). Natural
products can be obtained from varied sources, such as
plants, algae and fungi. This is particularly striking in
Argentina, where there is a huge biodiversity in its flora
and countless unexplored plant species.
Using a high-throughput screening technology developed in
our Lab (Carbajosa et al., 2019; Villafañez et al., 2019), we
analyzed a panel of 46 extracts obtained from native and
naturalized plant species from Argentina. An alkaloidal
extract from Zanthoxylum coco Gillies ex Hook. f. & Arn.
[Fagara coco (Gillies ex Hook. f. & Arn.) Engl.] (Fam.
Rutaceae), presented the most selective SL-induction activity,
being oxynitidine the most active compound. These findings
unveil a novel therapeutic activity of alkaloids from
Zanthoxylum-spp., which will be of interest as lead molecules
for future drug discovery projects.
MATERIALS AND METHODS
General Experimental Procedures
NMR spectra were recorded on a Bruker AVANCE II AV-400
instrument operating at 400.13 MHz for 1H and 100.63 MHz for
13C, while 2D spectra (COSY, HSQC, HMBC, and NOESY) were
obtained using standard Bruker software.
Chromatographic separations were performed by column
chromatography on silica gel 60 (0.063–0.200 mm),
preparative TLC on silica gel 60 F254 (0.2 mm thick) plates,
and HPLC. Preparative TLC separations were performed
under the following conditions: i) the amount of sample
applied was approximately 15 mg for 20 cm plate; ii) the
bands were visualized using ultraviolet light and Dragendorff
reagent; iii) compounds were eluted from the silica using hexane:
EtOAc (8:2).
HPLC separations were achieved on a Waters HPLC set
provided with binary pump (Waters 1525), Agilent column
(ZORBAX Eclipse XDB-C18, 9.4 × 250 mm, 5-μm), UV-Vis
detector with diode array (Waters 2998); a Rheodyne manual
injector valve, with 80 µl sample loop. Chromatograms were
processed with Empower software.
Plant Materials and Extracts Preparation
The plants were collected from December to March at time of
flowering. Botanical identification and authentication were
carried out by the botanists G. Ruiz and G. Barboza. Voucher
specimens have been deposited in the “Marcelino Sayago”
Herbarium, Catholic University of Córdoba, in the Herbarium
from the Museum of Natural Sciences, National University of
Salta and in the Botanical Museum of Córdoba, National
University of Córdoba (see Supplementary Table S1,
Supplementary Material, which includes the coordinates of
collections sites). The crude extracts were obtained by
maceration with ethanol or methanol and prepared by
exhaustive solvent removal.
Zanthoxylum coco was collected in Río Ceballos,
Departamento Colón, Córdoba, Argentina (31°09′00′S,
64°18′00″W). Fresh fruits (1,800 g) were minced and extracted
withMeOH (3 × 1 L). The solvent was then evaporated at reduced
pressure. The total residue was diluted with (500 ml, 10%)
aqueous HCl solution. Diatomaceous Earth was added, and
the homogenate was placed at 2°C for 12 h. Afterwards, the
aqueous phase was vacuum filtrated. The resulting fraction
was partitioned in CH2Cl2 (3 × 200 ml). The pH of the
aqueous acidic fraction was adjusted to 9 with NH4OH and
extracted with CH2Cl2 (6 × 150 ml). Organic extract was dried
over anhydrous Na2SO4, filtered, and evaporated to dryness at
reduced pressure to obtain 1.8 g of alkaloidal extract.
Bioguided Isolation of the Active Principle in
the Alkaloidal Extract From Zanthoxylum
coco
The alkaloidal extract was fractionated initially by silica gel 60G
chromatography. Elution with CH2Cl2:MeOH mixtures of
increasing polarity (100:0–80:20) afforded seven pools. The
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bioactive fractions pools (III and IV, 750 mg) were subjected to
CC with hexane-EtOAc mixtures of increasing polarity (100:
0–100:0) yielding five pools. Fractions 8–10 (pool II, 19 mg) was
further purified by preparative TLC with hexane:EtOAc (80:20)
to give dihydrochelerythrine (7.6 mg). The fractions 11–28 (pools
III and IV, 130 mg) were applied to a silica gel 60 G column using
hexane:EtOAc mixtures of increasing polarity (100:0–100:0) to
afford β-fagarine (9 mg), dictanmine (0.7 mg), and an impure
fraction (30 mg), with the latter being further analyzed by high
performance liquid chromatography (HPLC). The elution system
was composed by phase A: methanol: water [65 :35 (v:v)], phase
B: methanol : water [80 :20 (v:v)], and phase C: methanol : water
[87 :13 (v:v)]. The HPLC allowed to obtain (in order of elution):
3-(1,2-dihydroxyethyl)-4-methoxy-2(1H)-quinolinone (1.9 mg),
haplopine (1.1 mg), β-fagarine (14.5 mg), arnottianamide
(0.7 mg), 8-demethyloxychelerythrine (1.3 mg), oxynitidine
(2.3 mg), and oxychelerythrine (1.1 mg).
DNA Constructs and Short Hairping RNA
iRFP-C1 was a gift from Michael Davidson and Vladislav
Verkhusha (National Magnetic High Field Laboratory,
Tallahassee, FL; Addgene plasmid #54786; Filonov 2012);
shBRCA1 (TRCN0000010305, Sigma-Aldrich) was cloned into
pLKO.1-TRC vector through EcoRI and AgeI restriction sites;
and shSCR-pLKO.1 was described previously (Trucco et al.,
2014).
Cell Culture
HCT116p21−/− cells were kindly provided by Bert Vogelstein
(Johns Hopkins Medicine, Baltimore, MD). All the remaining
cells used in this study were obtained from ATCC. Cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM;
Thermo Fisher Scientific Inc.) supplemented with 10% fetal
bovine serum (FBS; GIBCO) and 1% penicillin/streptomycin
(Thermo Fisher Scientific Inc.). Control for Mycoplasma
contamination was performed periodically with a PCR-based
method with internal loading control. HCT116p21−/− BRCA-
deficient cells (and control cells) were generated as described
previously (Carbajosa et al., 2019). Each cell line co-expresses a
different fluorescent protein: shSCR (CFP) and shBRCA1 (iRFP).
The entire screening phase was performed with cells that did not
exceed five passages after transduction to avoid the positive
selection of cells with higher BRCA levels. Cell lines were used
for experimentation for no more than 20 passages from the main
frozen stock. Nitidine was obtained from Sigma-Aldrich (≥97%),
diluted in DMSO (Carlo Erba) and used at the indicated
concentrations.
Cell Survival Analysis
Equal numbers of cells were co-cultured or separately plated in
96 MW plates, and increasing doses of extracts/compounds were
tested. Six days post-treatment, total cell number of each cell
population was counted using automated flow cytometry with an
autosampler (Attune NxT, Thermo Fisher Scientific). The relative
survival of each cell population in comparison with the untreated
controls was determined to calculate SL induction by the different
treatments. The PARP inhibitor Olaparib (0.1 μM) was used as
positive control of the SL induction.
Protein Analysis
Western blot analysis was carried out essentially as previously
described in (Villafañez et al., 2019). The detection and
quantification were performed with Odyssey CLX System (LI-
COR Biosciences) using the proprietary Image Studio Software.
The following primary antibodies were used: α-phospho-Akt
(Ser473; Cell Signaling Technology, Cat# 9271); anti-β-Actin
was from (Sigma-Aldrich, Cat# A2228). As secondary
antibodies we used: goat α-mouse IRDye 680RD (LI-COR
Biosciences, Cat# P/N 925-68070) and goat α-rabbit IRDye
800CW (LI-COR Biosciences, Cat# P/N 925-32211).
Statistical Analysis
All experiments were executed by duplicate or triplicate. Graphs
and statistical analysis were performed using GraphPad Prism 5.0
(GraphPad Software), applying two-sided Student’s t-test and
ANOVA test as appropriate. Bars represent the mean value ± SD
Other calculations were performed using Microsoft Excel 2007.
RESULTS
Synthetic Lethal Screen Using a Collection
of Extracts From Argentinean Native or
Naturalized Plants
To identify novel SL interactions in BRCA1 deficient contexts, we
used an adaptation of a phenotypic screening platform developed
in our Lab (Carbajosa et al., 2019; Villafañez et al., 2019) to
evaluate a collection of plant extracts. Such collection comprises
extracts from 46 native or naturalized plant species from
Argentina. The plants belong to various families such as
Asteraceae, Bignoniaceae, Celastraceae, Solanaceae, Rutaceae,
among other (Supplementary Table S1). We achieved BRCA1
downregulation using short hairping RNAs (shRNAs). In our
phenotypic screening platform, two HCT116-derived cell lines
expressing shRNAs [shSCR (non-targeting scramble control) and
shBRCA1] tagged different fluorescent proteins (CFP and iRFP,
respectively) were co-cultured for 6 days in the presence of the
evaluated extracts at 2.5-fold serial dilutions: 50, 20, 8 and 3.2 μg/
ml (Figure 1 A). The final readout was the total cell number and
proportion of each population in each well, which was
determined by an acoustic flow cytometer. For screening
purposes, hits were defined by a variation greater than 3 SD
on two values derived from the differential impact of the extracts
on the BRCA1-deficient vs. BRCA1-proficient populations: 1) SL
induction fold: derived from the ratio of the proportion of
BRCA1-proficient/BRCA1-deficient cells in each well and 2)
survival difference: derived from the subtraction of the
survival of the BRCA1-deficient from the BRCA1-proficient
population. An optimal dose of the PARPi Olaparib (0.1 µM)
was used as a positive control of SL-induction (Figure 1;
Supplementary Figure S1A).
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A careful analysis of the screening results (Figure 1B;
Supplementary Table S2), considering both the synthetic
lethal fold and survival difference of the hits, focused our
attention on the alkaloidal extract of Zanthoxylum coco
(#2026). Following this initial finding, different Z. coco
extracts from leaves and fruits were tested, being the
alkaloidal extract obtained from fruits the most active one
(Supplementary Figure S1B). Such extract showed potent
SL-induction, but more importantly, it presented activity
within a concentration range where cytotoxicity was
evident almost exclusively in the BRCA1-deficient
population. This phenotype was observed using different
BRCA1-deficient cellular models (Figures 1C,D).
Noteworthy, at higher concentrations, the SL-induction
capacity of the extract was lost due to the increased
unspecific toxicity on the BRCA1-proficient cell line, as it
is also observed for the PARPi Olaparib (Supplementary
Figure S1A).
FIGURE 1 | Phenotypic screening reveals that alkaloidal extract of Zanthoxylum coco induces synthetic lethality in the BRCA1-deficient population. (A)
Experimental layout and detailed protocol used to assess synthetic lethality (SL) induction using a co-culture method of BRCA-proficient (shSCR) and BRCA1-deficient
(shBRCA1) isogenic HCT116p21−/− cell lines, generated by lentiviral transduction of the corresponding shRNA. Each cell line co-expresses a different fluorescent protein:
shSCR (CFP) and shBRCA1 (iRFP). Equal numbers of isogenic cells were then plated in 96 MW plates and treated with increasing doses (3.2, 8, 20, and 50 μg/ml)
of extracts from native/naturalized plant species of Argentina. Six days post-treatment, the co-cultured population was counted and categorized by the differential
expression of fluorescent proteins using automated flow cytometry with an autosampler. The total cell number of each population/well was determined by an acoustic
flow cytometer. PARP inhibitor Olaparib was used as positive control of SL-induction in each screening plate at 0.1 µM. (B) Screening results. The graph shows the fold
of SL induction and the survival difference after the treatment. Alkaloidal extract from Zanthoxylum cocowas identified as hit using the criteria of more than 3 SDs in any of
the variables. The table is part of Supplementary Table S2 and shows top five hits ordered according the survival difference parameter. (C) Results obtained in dose-
response experiments in HCT116p21−/− cell lines testing the Z. coco extract in a dose range close to that identified in the screening. The SL fold and the survival difference
parameters are detailed. (D) Validation of the SL response to Z. coco extract using nonisogenic MDA-MB pair of breast cancer cell lines in monoculture experiments:
MDA-MB-231BRCA1-WT vs. MDA-MB-436BRCA1-KO. Statistical analysis was performed using two-way ANOVA with Bonferroni post-test (**, p ≤ 0.01; *, p ≤ 0.05).
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FIGURE 2 | Bioguided separation of the alkaloidal extract of Zanthoxylum coco to isolate and identify the active principle responsible for synthetic lethality activity.
(A) Schematic representation of Bio-guided fractionation coupled to HPLC that led to the isolation and identification of 5 benzophenanthridine alkaloids:
dihydrochelerythrine, oxychelerythrine, 8-demethyloxychelerythrine, arnottianamine, and oxynitidine) and 4 furoquinoline alkaloids: (β-fagarine, dictamnine, haplopine,
and 3-(1,2-dihydroxyethyl)-4-methoxy-2(1H)-quinolinone). Dose response experiment using POOL I″ (B) and POOL II″ (C), showing the survival difference
between BRCA1-deficient and proficient cells after 6 days of treatment. Dose response experiment using isolated β-fagarine (D) and oxynitidine (E) from POOL I″ and
POOL II″, respectively, showing the survival difference between BRCA1-deficient and proficient cells after 6 days of treatment. Statistical analysis was performed using
two-way ANOVA with Bonferroni post-test (***, p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 0.05).
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Bio-Guided Fractionation Coupled to High
Performance Liquid Chromatography Led
to the Identification of Active Furoquinoline
and Benzophenanthridine Alkaloids
The active extract from Z. coco was subjected to bio-guided
fractionation as depicted in Figure 2A. Two fractions
exhibited the most robust SL-induction activity, being POOL
I″ less potent than POOL II″ (Figures 2B,C, respectively). POOL
I″ contained mostly β-fagarine (≥95%), yet this alkaloid presented
vestigial SL-induction in comparison to POOL I″ and POOL II″
(Figure 2D). This led us to hypothesize that SL-induction was
triggered by a minority compound or a synergy between minority
compounds. Therefore, POOL II″ was submitted to reverse-phase
HPLC (Figure 2A) to further isolate the active(s) principle(s)
responsible for the selective cytotoxicity. From POOL II″, seven
alkaloids were isolated, identified and tested for SL-induction.
Intriguingly, most of the alkaloids were inactive (Supplementary
Figure S2) and the minority compound oxynitidine (<5%),
presented the strongest SL-inducing activity (Figure 2E). In
summary, Z. coco active extract fractionation led to the isolation
of five benzophenanthridine alkaloids (dihydrochelerythrine,
oxychelerythrine, 8-demethyloxychelerythrine, arnottianamine,
and oxynitidine) (Krane et al., 1984) and 4 furoquinoline
alkaloids (β-fagarine, dictamnine, haplopine, and 3-(1,2-
dihydroxyethyl)-4-methoxy-2(1H)-quinolinone) (Adamska-
Szewczyk et al., 2016) (Supplementary Figure S2). The
structures of the isolated alkaloids were established based on
their NMR data and by comparison with those previously
reported.
The Commercially Available Alkaloid
Nitidine Is a Powerful Synthetic
Lethality-Inducer in BRCA1-Deficient Cells
Nitidine chloride (Figure 3A) is a bioactive benzophenanthridine
alkaloid found in species of the Zanthoxylum genus, particularly
in Zanthoxylum nitidum (Hu et al., 2006; Cai et al., 2007). It was
described to have anti-inflammatory, anti-parasitic, and
antifungal properties (Nhiem et al., 2020). Interestingly, this
metabolite was reported to possess potent antitumor activities
by inhibiting proliferation and inducing apoptosis in several types
of cancer models (Chen et al., 2012; Liao et al., 2013; Fang et al.,
2013; Cui et al., 2020; Nhiem et al., 2020). Since oxynitidine is the
6-oxo analogue of nitidine, we decided to test whether nitidine
also depicts selective cytotoxicity against BRCA1-deficient cells.
Surprisingly, nitidine exhibited strong SL-inducing activity, even
in the nanomolar range, and it was presumably at least 10 times
more potent than its 6-oxo analogue (Figure 3B). Presumably,
this could be a consequence of the quaternary amino group
present in nitidine, while oxynitidine has an amide functional
group. The positive charge density of both alkaloids is very
different, impacting in the interactions with the amino acids
present in target molecules and in its pharmacokinetic properties.
To validate the SL phenotype in different genetic
backgrounds, we performed survival experiments in two
breast cancer models knockout (KO) for BRCA1. We used
the non-isogenic pair of triple negative breast cancer MDA-
MB cell lines (MDA-231BRCA1-WT vs. MDA-436BRCA1-KO) and
the isogenic HCC1937 model (BRCA1KO vs. BRCA1C). We
found that nitidine triggered SL in both BRCA1-KO
backgrounds in a dose-response manner (Figures 3C,D).
Noticeably, these two models presented higher SL sensitivity
to nitidine and a wider dose-response range than the BRCA1-
deficient cells generated by downregulation of BRCA1 using
lentiviral shRNA (Figure 3B). Taken together, these data
suggest that nitidine treatment is synthetic lethal with
BRCA1 deficiency.
FIGURE 3 | Evaluation of nitidine as a synthetic lethality (SL)-inducer in
BRCA1-deficient cells. (A) Chemical structure of nitidine chloride.
Determination of SL induction using BRCA-proficient and BRCA-deficient
cells in a dose-response curve of nitidine after 6 days of treatment. The
isogenic shBRCA1 and shSCR HCT116p21−/− cells (B); the triple-negative
breast cancer MDA-MB-231BRCA1-WT and MDA-MB-436BRCA1-KO cells (C)
and the isogenic breast cancer HCC1937 BRCA1−/− and its complemented
counterpart (HCC1937 BRCA1C) cell lines (D) were used. Statistical analysis
was performed using two-way ANOVA with Bonferroni post-test (***, p ≤
0.001; **, p ≤ 0.01; *, p ≤ 0.05).
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AKT and Topoisomesase Inhibitors are
Powerful Synthetic Lethality-Inducers in
BRCA1-Deficient Cells
To explore the underlying mechanism of action associated to the
SL-induction triggered by nitidine, we explored different
hypotheses. While several biological properties were reported
for nitidine (Reviewed in Nhiem et al., 2020), we focused on two
main activities that might be responsible for its selective
antitumoral effect in BRCA1-deficient contexts. On the one
hand, it was described that nitidine disrupts AKT signaling
(Fang et al., 2013; Cheng et al., 2016; Ding et al., 2016), which
was recently reported to be involved in SL-induction in BRCA1-
deficient cells (Villafañez et al., 2019). On the other hand, nitidine
inhibits Topoisomerase I and Topoisomerase II activities (Fang
et al., 1993; Wang et al., 1993; Holden et al., 1999; Liu et al., 2018),
which were also reported to trigger SL in BRCA1−/− cellular
models (Maede et al., 2013). We initially confirmed that nitidine
inhibits AKT signaling using our experimental settings by
analyzing phospho-AKT levels in breast cancer cell line MDA-
MB231 (Figure 4A). Then, we evaluated the cytotoxic effect of
AKT inhibitor MK2206 (Figure 4B) and the Topoisomerase I
inhibitor Camptothecin (Figure 4C) in BRCA1-deficient cells.
Our results revealed that both inhibitors induced SL in BRCA1-
KO cells (Figures 4B,C). Taking together, our findings indicate
that AKT and topoisomerases are the potential molecular targets
responsible of nitidine-triggered SL-induction in BRCA1-
deficient cells.
DISCUSSION
Cancer is responsible for millions of deaths worldwide every year
(Torre et al., 2016) (https://gco.iarc.fr/). Carcinogenesis is a
multi-step process at which several mechanisms that control
cell division sequentially fail, leading to transformed
phenotypes with unrestricted cell proliferation and survival
(Hann and Weinberg 2007; Puisieux et al., 2018). In such a
complex disease, redundancies and complexities of biological
pathways often lead to compensation, treatment failure and
resistance to targeted therapies (Ramsay et al., 2018).
Moreover, single-target therapeutic approaches may be
affected by side effects and tissue toxicity, resulting in reduced
efficacy and a decreased quality of life for patients (Anighoro et al.
, 2014). In contrast, specific drug combinations or multi-targeted
therapy are designed to achieve more durable disease control,
resulting from simultaneous blockade of disease-relevant targets
(Anighoro et al., 2014). Moreover, it was also suggested that
molecules with multitarget mechanism of action may possess a
safer profile compared to single-target ones (Bolognesi, 2013;
Ramsay et al., 2018). Therefore, successful treatments for cancer
may require targeting multiple disease-causing pathways to
achieve additive or synergistic effects, as well as overcoming
drug resistance. In consequence, many novel drug discovery
and development strategies are being focused on targeting
multiple molecular pathways, either with drug combinations
or through the design of single compounds that target
multiple proteins: an approach known as polypharmacology
(Anighoro et al., 2014; Ho et al., 2018; Lim et al., 2019).
One of the key advantages of using natural products instead of
synthetic compounds in drug discovery is that natural products
are likely to be multi-target compounds. Nitidine is a common
alkaloid found in many Zanthoxylum species, and it has been
reported to suppress cell proliferation, to stimulate apoptosis, to
induce cell cycle arrest, and to retard migration, invasion and
metastasis in a variety of malignancies via multiple molecular
mechanisms (Cui et al., 2020; Nhiem et al., 2020). In this work, we
unveil a potential polypharmacological capacity for nitidine,
which might be responsible for its synthetic lethal activity
against BRCA1-deficient cells. Our working model is that the
selective and robust antitumoral activity of nitidine treatment is a
FIGURE 4 | Analysis of the cytotoxic effect of AKT and Topoisomerase I
inhibition in BRCA-deficient cells. (A) western blot confirming the efficient
impairment of AKT phosphorylation after the treatment with different doses of
nitidine (0, 2.5, 5 and 10 µM) in breast cancer cell lines MDA-MB-236 for
3 h. β-Actin was used as loading control. The normalized p-AKT/β-Actin ratios
are shown. Determination of synthetic lethality induction in MDA-MB-
231BRCA1-WT and MDA-MB-436BRCA1-KO cells after 6 days of treatment with
AKT inhibitor, MK2206 (B), or Topoisomerase I inhibitor, Camptothecin (C) in
a dose-response range. Statistical analysis was performed using two-way
ANOVA with Bonferroni post-test (***, p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 0.05).
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consequence of the simultaneous targeting of two molecular
pathways of central relevance in BRCA1−/− models: AKT and
topoisomerases (Maede et al., 2013; Villafañez et al., 2019).
Interestingly, while these studies shown that the inhibition of
such targets are linked to the impaired viability of BRCA1-
deficient cells in vitro, these types of approaches are not yet
established as alternatives for the treatment of BRCA1-related
cancers. However, a couple of recent reports shed light on this
direction. First, it was shown that AKT inhibition using the
investigational drug MK-2206 suppresses the initiation and
progression of BRCA1-associated mammary tumors (Baek
et al., 2018). Second, a recent report indicates that BRCA
deficiencies predict response to topoisomerase I inhibitors
in 40 PDXs obtained from triple-negative breast cancers
patients (Coussy et al., 2020).
The findings in this work also highlight the importance of
exploring alkaloids from the Zanthoxylum genus. This is one of
the biggest genera belonging to the Rutaceae family, which
includes 212 species widely distributed in areas with warm or
tropical climate. Many biological activities were described in
Zanthoxylum spp., such as antimicrobial, anti-inflammatory,
antioxidant, and in particular cytotoxic activity. Even though
several classes of compounds have been isolated from this genus,
alkaloids are the components with the most interesting biological
properties (Nhiem et al., 2020). Particularly, this genus holds
elevated levels of benzophenanthridine alkaloids that not only
revealed their potential cytotoxic in vitro but also their capability
to inhibit tumor growth in vivo through several mechanisms
(Nhiem et al., 2020). Furoquinoline alkaloids are also found in
Zanthoxylum species, and they show cytotoxic activity as well
(Yang et al., 2009; Nhiem et al., 2020). The findings of this work
unveil an intriguing new aspect of the alkaloids from
Zanthoxylum-spp., positioning them as promising lead
molecules for future drug discovery projects.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation, to any
qualified researcher.
AUTHOR CONTRIBUTIONS
Conceptualization, IG, MP, MC, VN, and GS; methodology, IG,
MP, AP, MEG, and MLG; acquisition of data: MP, MCC, JB, GB,
and JO; investigation, IG, MP, and MEG; writing-original draft,
IG and GS; supervision, JB, MC, VN, and GS; project
Administration, GS; funding acquisition: GS. All authors
contributed to manuscript revision, read and approved the
submitted version.
FUNDING
This work was supported by a consortium grant from FONCyT
and the Trust in Science program (Global Health R&D) from
GlaxoSmithKline (PAE-GLAXO 2014-0005). Additional
support came from grants: PICT 2015-0543, PICT 2016-0235
from FONCyT and from National Institute of Cancer of
Argentina (INC-2018). IG and MG were supported by
fellowships from PAE-GLAXO 2014-0005. MFP was
supported by fellowships from the National Institute of
Cancer and CONICET. MG, JO, JB, MC, GB, VN, and GS
are researchers from CONICET. AP is researcher from UNC.
The authors declare that this study received funding from the
Trust in Science Program of GlaxoSmithKline. The funder was
not involved in the study design, collection, analysis,
interpretation of data, the writing of this article or the
decision to submit it for publication.
ACKNOWLEDGMENTS
The authors thank the flow cytometry, microscopy, and cell
culture facilities of CIBICI-CONICET for technical support.
SUPPLEMENTARY MATERIAL




Adamska-Szewczyk, A., Glowniak, K., and Baj, T. (2016). Furochinoline alkaloids
in plants from Rutaceae family - a review. Curr. Issues Pharm. Med. Sci. 29,
33–38. doi:10.1515/cipms-2016-0008
Anighoro, A., Bajorath, J., and Rastelli, G. (2014). Polypharmacology: challenges
and opportunities in drug discovery. J. Med. Chem. 57 (19), 7874–7887. doi:10.
1021/jm5006463
Baek, H. J., Kim, S. E., Kim, J. K., Shin, D. H., Kim, T. H., Kim, K. G., et al. (2018).
Inhibition of AKT suppresses the initiation and progression of BRCA1-
associated mammary tumors. Int. J. Biol. Sci. 14 (13), 1769. doi:10.7150/ijbs.
29242
Bindseil, K. U., Jakupovic, J.,Wolf, D., Lavayre, J., Leboul, J., andVanDer Pyl, D. (2001).
Pure compound libraries; a new perspective for natural product based drug
discovery. Drug Discovery Today 6, 840–847. doi:10.1016/s1359-6446(01)01856-6
Bolognesi, ML (2013). Polypharmacology in a single drug: multitarget drugs. Curr.
Med. Chem. 20, 1639–45. doi:10.2174/0929867311320130004
Cai, M., Zhou, Y., Wang, X., Li, R., Liao, X., and Ding, L. (2007). A Rapid structural
characterization of isomeric benzo[c]phenanthridine alkaloids from the roots
of Zanthoxylum nitidium by liquid chromatography combined with
electrospray ionization tandem mass spectrometry. Rapid Commun. Mass
Spectrom. 21, 1931–1936. doi:10.1002/rcm.3045
Canaani, D. (2014). Application of the concept synthetic lethality toward
anticancer therapy: a promise fulfilled? Cancer Letters 352 (1), 59–65.
doi:10.1016/j.canlet.2013.08.019
Carbajosa, S., Pansa, M. F., Paviolo, N. S., Castellaro, A. M., Andino, D. L., Nigra, A.
D., et al. (2019). Polo-like kinase 1 inhibition as a therapeutic approach to
selectively target BRCA1-deficient cancer cells by synthetic lethality induction.
Clin. Cancer Res. 25 (13), 4049–4062. doi:10.1158/1078-0432.ccr-18-3516
Chen, J., Wang, J., Lin, L., He, L., Wu, Y., Zhang, L., et al. (2012). Inhibition of
STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and
Frontiers in Pharmacology | www.frontiersin.org December 2020 | Volume 11 | Article 5938458
García et al. Nitidine is Synthetic Lethal With BRCA1 Deficiency
growth of human gastric cancer. Molecular Cancer Therapeutics 11, 277–287.
doi:10.1158/1535-7163.mct-11-0648
Cheng, Z., Guo, Y., Yang, Y., Kan, J., Dai, S., Helian, M., et al. (2016). Nitidine
chloride suppresses epithelial-to-mesenchymal transition in osteosarcoma cell
migration and invasion through Akt/GSK-3β/Snail signaling pathway. Oncol.
Rep. 36, 1023–1029. doi:10.3892/or.2016.4846
Coussy, F., El-Botty, R., Château-Joubert, S., Dahmani, A., Montaudon, E.,
Leboucher, S., et al. (2020). BRCAness, SLFN11, and RB1 loss predict
response to topoisomerase I inhibitors in triple-negative breast cancers. Sci.
Transl. Med. 12 (531), eaax2625. doi:10.1126/scitranslmed.aax2625
Cui, Y., Wu, L., Cao, R., Xu, H., Xia, J., Wang, Z. P., et al. (2020). Antitumor
functions and mechanisms of nitidine chloride in human cancers. J. Cancer 11,
1250–1256. doi:10.7150/jca.37890
D’Andrea, A. D. (2018). Mechanisms of PARP inhibitor sensitivity and
resistance. DNA Repair (Amst). 71, 172–176. doi:10.1016/j.dnarep.2018.08.
021
Ding, F., Liu, T., Yu, N., Li, S., Zhang, X., Zheng, G., Lv, C., Mou, K., Xu, J., Li, B.,
Wang, S., and Song, H. (2016). Nitidine chloride inhibits proliferation, induces
apoptosis via the AKT pathway and exhibits a synergistic effect with
doxorubicin in ovarian cancer cells. Mol. Med. Rep. 14, 2853–2859. doi:10.
3892/mmr.2016.5577
Dutta, S., Mahalanobish, S., Saha, S., Ghosh, S., and Sil, P. C. (2019). Natural
products: an upcoming therapeutic approach to cancer. Food and Chemical
Toxicology 128, 240–255. doi:10.1016/j.fct.2019.04.012
Fackenthal, J. D., and Olopade, O. I. (2007). Breast cancer risk associated with
BRCA1 and BRCA2 in diverse populations.Nat. Rev. Cancer 7, 937–948. doi:10.
1038/nrc2054
Fang, S. D., Wang, L. K., and Hecht, S. M. (1993). Inhibitors of DNA topoisomerase
I isolated from the roots of Zanthoxylum nitidum. J. Org. Chem. 58, 5025–5027.
doi:10.1021/jo00071a001
Fang, Z., Tang, Y., Jiao, W., Xing, Z., Guo, Z., Wang, W., Shi, B., Xu, Z., and Liu, Z.
(2013). Nitidine chloride inhibits renal cancer cell metastasis via suppressing
AKT signaling pathway. Food Chem. Toxicol. 60, 246–251. doi:10.1016/j.fct.
2013.07.062
Filonov, G. S., Piatkevich, K. D., Ting, L.-M., Zhang, J., Kim, K., and
Verkhusha, V. V. (2011). Bright and stable near-infrared fluorescent
protein for in vivo imaging. Nat. Biotechnol. 29, 757–761. doi:10.1038/
nbt.1918
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J.,
et al. (2019). Maintenance olaparib for germline BRCA-mutated metastatic
pancreatic cancer. N. Engl. J. Med. 381, 317–327. doi:10.1056/
nejmoa1903387
González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill,
W., Mirza, M. R., et al. (2019). Niraparib in patients with newly diagnosed
advanced ovarian cancer. N. Engl. J. Med. 381, 2391–2402. doi:10.1056/
nejmoa1910962
Hann, W. C., and Weinberg, R. A. (2007). Rules for making human tumor cells. N.
Engl. J. Med. 347, 1593–1603. doi:10.1056/NEJMra021902
Harvey, A. L. (2008). Natural products in drug discovery.Drug Discovery Today 13,
894–901. doi:10.1016/j.drudis.2008.07.004
Henkel, T., Brunne, R. M., Müller, H., and Reichel, F. (1999). Statistical
investigation into the structural complementarity of natural products and
synthetic compounds. Angew. Chem. Int. Ed. 38, 643–647. doi:10.1002/(sici)
1521-3773(19990301)38:5<643::aid-anie643>3.0.co;2-g
Ho, T. T., Tran, Q. T., and Chai, C. L. (2018). The polypharmacology of natural
products. Future Medicinal Chemistry 10, 1361–1368. doi:10.4155/fmc-2017-
0294
Holden, J. A., Wall, M. E., Wani, M. C., andManikumar, G. (1999). Human DNA
Topoisomerase I: Quantitative Analysis of the Effects of Camptothecin
Analogs and the Benzophenanthridine Alkaloids Nitidine and 6-
Ethoxydihydronitidine on DNA Topoisomerase I-Induced DNA Strand
Breakage. Archives of Biochemistry and Biophysics 370, 66–76. doi:10.
1006/abbi.1999.1355
Hu, J., Zhang, W.-D., Liu, R.-H., Zhang, C., Shen, Y.-H., and Li, H.-L. (2006).
Benzophenanthridine alkaloids from Zanthoxylum nitidum (Roxb.) DC,
and their analgesic and anti-inflammatory activities. Chem. Biodivers. 3,
990–995.
King, M.-C., King, M., Marks, J. H., and Mandell, J. B. (2003). Breast and ovarian
cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302
(5645), 643–646. doi:10.1126/science.1088759
Kohn, E. C., Lee, J.-m., and Ivy, S. P. (2017). TheHRDDecision-Which PARP
Inhibitor to Use for Whom andWhen. Clin. Cancer Res. 23, 7155–7157. doi:10.
1158/1078-0432.ccr-17-2186
Krane, B. D., Fagbule, M. O., and Shamma, M. (1984). The benzophenanthridine
alkaloids. J. Nat. Prod. 47, 1–43. doi:10.1021/np50031a001
Liao, J., Xu, T., Zheng, J.-X., Lin, J.-M., Cai, Q.-Y., Yu, D.-B., and Peng, J. (2013).
Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through
the suppression of the JAK1/STAT3 signaling pathway. Int. J. Mol. Med. 32,
79–84. doi:10.3892/ijmm.2013.1358
Lim, H., He, D., Qiu, Y., Krawczuk, P., Sun, X., and Xie, L. (2019). Rational
discovery of dual-indication multi-target pde/kinase inhibitor for precision
anti-cancer therapy using structural systems pharmacology. PLoS Comput. Biol.
15, e1006619–21. doi:10.1371/journal.pcbi.1006619
Liu, L.-M., Xiong, D.-D., Lin, P., Yang, H., Dang, Y.-W., and Chen, G. (2018).
DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may
be direct targets of nitidine chloride. Int. J. Oncol. 53, 1897–1912. doi:10.
3892/ijo.2018.4531
Lord, C. J., and Ashworth, A. (2016). BRCAness revisited. Nat. Rev. Cancer 16,
110–120. doi:10.1038/nrc.2015.21
Lord, C. J. and Ashworth, A. (2017). PARP inhibitors: Synthetic lethality in the
clinic. Science 355, 1152–1158. doi:10.1126/science.aam7344
Maede, Y., Shimizu, H., Fukushima, T., Kogame, T., Nakamura, T., Miki, T.,
Takeda, S., Pommier, Y., and Murai, J. (2013). Differential and common DNA
repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40
repair cell screen panel. Mol. Cancer Ther. Therapeutics 13, 214–220. doi:10.
1158/1535-7163.mct-13-0551
Newman, D. J., and Cragg, G. M. (2020). Natural products as sources of new drugs
over the nearly four decades from 01/1981 to 09/2019. J. Nat. Prod. 83, 770–803.
doi:10.1021/acs.jnatprod.9b01285
Nhiem, N. X., Quan, P. M., and Thi Hong Van, N. (2020). Chapter: alkaloids and
their pharmacology effects from Zanthoxylum genus. IntechOpen. http://dx.doi.
org/10.5772/intechopen.91685
Nijman, S. M. B., and Friend, S. H. (2013). Potential of the Synthetic Lethality
Principle. Science 342, 809–811. doi:10.1126/science.1244669
Noordermeer, S. M., and van Attikum, H. (2019). PARP inhibitor resistance: a tug-
of-war in BRCA-mutated cells. Trends Cell Biol. 29 (10), 820–834. doi:10.1016/j.
tcb.2019.07.008
Puisieux, A., Pommier, R. M., Morel, A.-P., and Lavial, F. (2018). Cellular pliancy
and the multistep process of tumorigenesis. Cancer Cell 33, 164–172. doi:10.
1016/j.ccell.2018.01.007
Ramsay, R. R., Popovic-Nikolic, M. R., Nikolic, K., Uliassi, E., and Bolognesi, M. L.
(2018). A perspective on multi-target drug discovery and design for complex
diseases. Clin. Transl. Med. 7, 3. doi:10.1186/s40169-017-0181-2
Rodrigues, T., Reker, D., Schneider, P., and Schneider, G. (2016). Counting on
natural products for drug design. Nat. Chem. 8, 531–541. doi:10.1038/nchem.
2479
Ryan, C. J., Bajrami, I., and Lord, C. J. (2018). Synthetic lethality and cancer –
penetrance as the major barrier. Trends Cancer 4, 671–683. doi:10.1016/j.trecan.
2018.08.003
Saleh, N., and Copur, M. S. (2019). Overview: FDA approval of olaparib
maintenance for BRCA-mutated. Oncology (Williston Park) 33 (7),
629388
Schmidt, B. M., Ribnicky, D. M., Lipsky, P. E., and Raskin, I. (2007). Revisiting the
ancient concept of botanical therapeutics. Nat. Chem. Biol. 3, 360–366. doi:10.
1038/nchembio0707-360
Sharma, B., Preet Kaur, R., Raut, S., and Munshi, A. (2018). BRCA1 mutation
spectrum, functions, and therapeutic strategies: the story so far. Curr. Probl.
Cancer 42, 189–207. doi:10.1016/j.currproblcancer.2018.01.001
Simhadri, S., Vincelli, G., Huo, Y., Misenko, S., Foo, T. K., Ahlskog, J., Sørensen, C.
S., Oakley, G. G., Ganesan, S., Bunting, S. F., and Xia, B. (2019). PALB2 connects
BRCA1 and BRCA2 in the G2/M checkpoint response. Oncogene 38,
1585–1596. doi:10.1038/s41388-018-0535-2
Takaoka, M., andMiki, Y. (2018). BRCA1 gene: function and deficiency. Int. J. Clin.
Oncol. 23, 36–44. doi:10.1007/s10147-017-1182-2
Frontiers in Pharmacology | www.frontiersin.org December 2020 | Volume 11 | Article 5938459
García et al. Nitidine is Synthetic Lethal With BRCA1 Deficiency
Thomford, N. E., Senthebane, D. A., Rowe, A., Munro, D., Seele, P., Maroyi, A., and
Dzobo, K. (2018). Natural products for drug discovery in the 21st century:
innovations for novel drug discovery. Ijms 19, 1578, 1578. doi:10.3390/
ijms19061578
Torre, L. A., Siegel, R. L., Ward, E. M., and Jemal, A. (2016). Global Cancer
Incidence and Mortality Rates and Trends–An Update. Cancer Epidemiol.
Biomark. Prev. 25, 16–27. doi:10.1158/1055-9965.epi-15-0578
Trendowski, M. (2015). Recent advances in the development of antineoplastic
agents derived from natural products. Drugs 75, 1993–2016. doi:10.1007/
s40265-015-0489-4
Trucco, L. D., Andreoli, V., Núñez, N. G., Maccioni, M., and Bocco, J. L. (2014).
Krüppel-like factor 6 interferes with cellular transformation induced by the H-
ras oncogene. FASEB. J. 28, 5262–5276. doi:10.1096/fj.14-251884
Venkitaraman, A. R. (2014). Tumour suppressor mechanisms in the control of
chromosome stability: insights from BRCA2.Mol. Cell 37, 95–99. doi:10.14348/
molcells.2014.2346
Villafañez, F., García, I. A., Carbajosa, S., Pansa, M. F., Mansilla, S., Llorens, M. C.,
et al. (2019). AKT inhibition impairs PCNA ubiquitylation and triggers
synthetic lethality in homologous recombination-deficient cells submitted to
replication stress. Oncogene 38 (22), 4310–4324. doi:10.1038/s41388-019-
0724-7
Wang, L. K., Johnson, R. K., and Hecht, S. M. (1993). Inhibition of topoisomerase I
function by nitidine and fagaronine. Chem. Res. Toxicol. 6, 813–818. doi:10.
1021/tx00036a010
Yang, C.-H., Cheng, M.-J., Lee, S.-J., and Yang, C.-W. (2009). econdary
metabolites and cytotoxic activities from the stem bark of Zanthoxylum
nitidum molucca islands, New Guinea, South China, Ryukyus, and at low
altitudes throughout. Helv. Chim. Acta 6, 846–857. doi:10.1002/cbdv.
200800107
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Garcia, Pansa, Pacciaroni, García, Gonzalez, Oberti, Bocco,
Carpinella, Barboza, Nicotra and Soria. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org December 2020 | Volume 11 | Article 59384510
García et al. Nitidine is Synthetic Lethal With BRCA1 Deficiency
